Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $191.44 million. The enterprise value is $209.41 million.
| Market Cap | 191.44M |
| Enterprise Value | 209.41M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 269.64 million shares outstanding. The number of shares has increased by 40.60% in one year.
| Current Share Class | 269.64M |
| Shares Outstanding | 269.64M |
| Shares Change (YoY) | +40.60% |
| Shares Change (QoQ) | +5.92% |
| Owned by Insiders (%) | 3.61% |
| Owned by Institutions (%) | 27.00% |
| Float | 238.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 94.96 |
| Forward PS | 21.78 |
| PB Ratio | 13.56 |
| P/TBV Ratio | 16.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 103.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.93, with a Debt / Equity ratio of 5.72.
| Current Ratio | 3.93 |
| Quick Ratio | 3.03 |
| Debt / Equity | 5.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.69 |
Financial Efficiency
Return on equity (ROE) is -409.47% and return on invested capital (ROIC) is -71.49%.
| Return on Equity (ROE) | -409.47% |
| Return on Assets (ROA) | -51.48% |
| Return on Invested Capital (ROIC) | -71.49% |
| Return on Capital Employed (ROCE) | -119.20% |
| Weighted Average Cost of Capital (WACC) | 16.40% |
| Revenue Per Employee | $10,957 |
| Profits Per Employee | -$517,484 |
| Employee Count | 184 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 9.34 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.86% in the last 52 weeks. The beta is 2.46, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.46 |
| 52-Week Price Change | -68.86% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 37.90 |
| Average Volume (20 Days) | 17,988,393 |
Short Selling Information
The latest short interest is 36.71 million, so 13.61% of the outstanding shares have been sold short.
| Short Interest | 36.71M |
| Short Previous Month | 40.14M |
| Short % of Shares Out | 13.61% |
| Short % of Float | 15.41% |
| Short Ratio (days to cover) | 4.64 |
Income Statement
In the last 12 months, Humacyte had revenue of $2.02 million and -$95.22 million in losses. Loss per share was -$0.55.
| Revenue | 2.02M |
| Gross Profit | -81.72M |
| Operating Income | -112.49M |
| Pretax Income | -97.59M |
| Net Income | -95.22M |
| EBITDA | -105.19M |
| EBIT | -112.49M |
| Loss Per Share | -$0.55 |
Balance Sheet
The company has $48.54 million in cash and $66.50 million in debt, with a net cash position of -$17.96 million or -$0.07 per share.
| Cash & Cash Equivalents | 48.54M |
| Total Debt | 66.50M |
| Net Cash | -17.96M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 11.62M |
| Book Value Per Share | 0.05 |
| Working Capital | 47.41M |
Cash Flow
In the last 12 months, operating cash flow was -$101.55 million and capital expenditures -$831,000, giving a free cash flow of -$102.38 million.
| Operating Cash Flow | -101.55M |
| Capital Expenditures | -831,000 |
| Depreciation & Amortization | 7.30M |
| Net Borrowing | 37.67M |
| Free Cash Flow | -102.38M |
| FCF Per Share | -$0.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,579.76% |
| Pretax Margin | -4,840.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.60% |
| Shareholder Yield | -40.60% |
| Earnings Yield | -49.74% |
| FCF Yield | -53.48% |
Analyst Forecast
The average price target for Humacyte is $2.05, which is 188.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.05 |
| Price Target Difference | 188.73% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 281.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -10.63 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.63 |
| Piotroski F-Score | 4 |